Market Place
Sourcing Support
Bayer`s Kerendia Reduces Cardio Death Risk By 16% In Heart Failure Patients
02 Sep 2024 //
FIERCE PHARMA
ESC Congress 2024: Bayer to Present Phase III KERENDIA® (finerenone) Data
29 Aug 2024 //
BUSINESSWIRE
Bayer`s KERENDIA® Achieves Primary Endpoint In FINEARTS-HF Study
05 Aug 2024 //
BUSINESSWIRE
Bayer to present real-world study data of Kerendia for the progression of CKD
25 May 2024 //
PHARMABIZ
Bayer reports drop in Q1 sales amidst patent litigation challenges
14 May 2024 //
PHARMACEUTICAL TECHNOLOGY
Finerenone CKD/T2D/Heart Failure Pooled Analysis Design At Heart Failure 2024
13 May 2024 //
BUSINESSWIRE
Bayer KERENDIA Data At Heart Failure Congress 2024
10 May 2024 //
BUSINESSWIRE
Data Provides Additional Insights on Hyperkalemia and Safety of Kerendia
04 Nov 2023 //
BUSINESSWIRE
New Kerendia™ (finerenone) data show impact of early albuminuria reduction
02 Nov 2023 //
PRESS RELEASE
New Human Biomarker Findings Support Mechanism of Action of Kerendia
02 Nov 2023 //
BUSINESSWIRE
USDMF for Finerenone API has been submitted to the USFDA
29 Sep 2023 //
PRESS RELEASE
Bayer Expands Clinical Devp Program Investigating Finerenone for Heart Failure
31 Aug 2023 //
BUSINESSWIRE
Bayer’s Kerendia Included in Latest Focused Clinical Updates from EU Cardiology
31 Aug 2023 //
BUSINESSWIRE
CPC Announces Initiation of MOONRAKER Program - 3 Trials Evaluating Finerenone
24 Aug 2023 //
ACCESSWIRE
Bayer to Investigate Finerenone in Ph III Study in Adults Withckd With Ty1 D
22 Jun 2023 //
BUSINESSWIRE
Bayer to present data on Kerendia from comprehensive clinical trial program
15 Jun 2023 //
PRESS RELEASE
China NMPA grants expanded indication of Bayer’s Kerendia
19 May 2023 //
PHARMABIZ
Kerendia™ (finerenone) granted expanded indication in China
17 May 2023 //
PRESS RELEASE
Bayer`s potential blockbusters Nubeqa, Kerendia thrive in Q1
11 May 2023 //
FIERCE PHARMA
Bayer`s Kerendia (Finerenone) Approved In Europe
20 Feb 2023 //
EMA
Kerendia granted expanded indication in EU for patients with CKD
11 Feb 2023 //
PHARMABIZ
New therapy option Kerendia reduces cardio-renal risk in chronic kidney disease
06 Dec 2022 //
PRESS RELEASE
Bayer starts work on $43M+ expansion of OTC manufacturing site in Pennsylvania
03 Dec 2022 //
ENDPTS
Scottish Medicines Consortium approves Bayer’s Kerendia for NHS Scotland
02 Dec 2022 //
PHARMAFILE
Bayer to Highlight Additional Analyses From Comprehensive KERENDIA (finerenone)
02 Nov 2022 //
BUSINESSWIRE
Bayer’s KERENDIA Recommended as Part of Comprehensive Treatment Strategy
27 Oct 2022 //
BUSINESSWIRE
Bayer KERENDIA Receives Updated Label to Include Findings From PIII FIGARO-DKD
01 Sep 2022 //
BUSINESSWIRE
Bayer’s Kerendia Cuts Death in Diabetes, Chronic Kidney Disease
30 Aug 2022 //
FIERCEPHARMA
Bayer launches Kerendia to slow down progression of CKD
25 Aug 2022 //
PHARMABIZ
Bayer to Present Data From CVS Portfolio, Presentation for KERENDIA
22 Aug 2022 //
BUSINESSWIRE
Bayer’s KERENDIA Receives Recommendations From ADA With CKD Associated With T2D
28 Jun 2022 //
BUSINESSWIRE
Bayer’s Kerendia to compete against SGLT-2 inhibitors
11 May 2022 //
KOREABIOMED
Bayer Presents New Subgroup Analyses for KERENDIA for CKD Associated With T2D
04 Apr 2022 //
BUSINESSWIRE
Bayer gets Japanese MHLW marketing approval for Kerendia in CKD and T2D
29 Mar 2022 //
PHARMABIZ
Bayer`s Biologic Kerendia (Finerenone) Receives Approval in Europe
11 Mar 2022 //
EMA
MHRA authorisation of new treatment for CKD associated with diabetes
09 Mar 2022 //
PHARMAFILE
EC grants MAA to Bayer’s Kerendia for CKD associated with type 2 diabetes
22 Feb 2022 //
PHARMABIZ
Evofem Biosciences, Orion Biotechnology Enter OB-002 Alliance
20 Dec 2021 //
CONTRACTPHARMA
Bayer Presented New Analyses Investigating KERENDIA on Cardiovascular Outcomes
18 Nov 2021 //
BUSINESSWIRE
Bayer bullish on Kerendia after SGLT2 combo showing
09 Nov 2021 //
FIERCEPHARMA
Bayer to present new analyses adding to the depth of knowledge on KERENDIA®
27 Oct 2021 //
BUSINESSWIRE
Bayer Phase III trial results prove positive for diabetes patients
04 Oct 2021 //
PHARMAFILE
Bayer initiates phase III FIND-CKD study of Kerendia in nondiabetic CKD
22 Sep 2021 //
PHARMABIZ
Bayer Extends Clinical Development Program for KERENDIA With PIII Study in CKD
20 Sep 2021 //
BUSINESSWIRE
Bayer`s Kerendia racks up cardio benefits in outcomes trials
30 Aug 2021 //
FIERCEPHARMA
Finerenone Improves Cardiovascular, Renal Outcomes in Patients With CKD & T2DM
28 Aug 2021 //
ESCARDIO
Bayer Announces KERENDIA® Reduces the Risk of Cardiovascular Outcomes
28 Aug 2021 //
BUSINESSWIRE
Bayer touts Kerendia`s blockbuster potential
05 Aug 2021 //
FIERCEPHARMA
FDA Approval of Kerendia to Help Slow Kidney Disease and Failure linked with T2D
15 Jul 2021 //
PR NEWSWIRE
Bayer’s Kerendia approved in the US to slow CKD in type 2 diabetes patients
13 Jul 2021 //
PHARMATIMES
FDA Approves Drug to Reduce Risk of Serious Kidney and Heart Complication
12 Jul 2021 //
FDA
Bayer’s KERENDIA® (finerenone) Receives U.S. FDA Approval
09 Jul 2021 //
BUSINESSWIRE
Bayer gets USFDA nod for KERENDIA (finerenone) to treat CKD associated with T2DM
09 Jul 2021 //
EXPRESS PHARMA
Bayer wins priority review for CKD program finerenone after PhIII data
14 Jan 2021 //
ENDPTS
Bayer`s heart drug helps patients regardless of medical history
17 Nov 2020 //
FIERCE BIOTECH
Bayer submits marketing authorization applications for finerenone in the U.S.
09 Nov 2020 //
PRESS RELEASE
Bayer`s heart failure pill hinders kidney, heart diseases
09 Jul 2020 //
FIERCE BIOTECH
